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Introduction: A faster andmore accurate self-report screener for early psychosis is needed to promote early iden-
tiﬁcation and intervention.
Methods: Self-report Likert-scale survey items were administered to individuals being screened with the Struc-
tured Interview for Psychosis-risk Syndromes (SIPS) and followed at eight early psychosis clinics. An a priori an-
alytic plan included Spectral Clustering Analysis to reduce the item pool, followed by development of Support
Vector Machine (SVM) classiﬁers.
Results: The cross-validated positive predictive value (PPV) of the EPSI at the default cut-off (76.5%) exceeded
that of the clinician-administered SIPS (68.5%) at separating individuals who would not convert to psychosis
within 12 months from those who either would convert within 12 months or who had already experienced a
ﬁrst episode psychosis (FEP). When used in tandem with the SIPS on clinical high risk participants, the EPSI in-
creased the combined PPV to 86.6%. The SVM classiﬁed as FEP/converters only 1% of individuals in non-clinical
and 4% of clinical low risk populations. Sensitivity of the EPSI, however, was 51% at the default cut-off.
Discussion: The EPSI identiﬁes, comparably to the SIPS but in less time andwith fewer resources, individuals who
are either at very high risk to develop a psychotic disorder within 12months or who are already psychotic. At its
default cut-off, EPSI misses 49% of current or future psychotic cases. The cut-off can, however, be adjusted based
on purpose. The EPSI is the ﬁrst validated assessment to predict 12-month psychotic conversion. An online
screening system, www.eps.telesage.org, is under development.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Waiting to treat symptoms of schizophrenia and other psychoses
until well after symptoms have developed limits the possibility of
successful treatment. A newer approach is to identify individuals who
are at increased risk of developing psychotic disorders in order to pre-
vent progression to frank illness and reduce the associated functional
disability (Kline and Schiffman, 2014). The Structured Interview for
Psychosis-Risk Syndromes (SIPS) was developed to identify individuals
at clinical high risk (CHR) for psychosis, to evaluate the natural history
of the illness during the prodromal period, and to assess response to in-
terventions to prevent progression (Miller et al., 1999, 2002;McGlashan
et al., 2001). The SIPS semi-structured interview is the “gold standard”
early psychosis assessment in North America, yet it takes about
90 min to administer. In addition, extensive training and certiﬁcation
are required to assure high inter-rater reliability (Miller et al., 2003).
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The Psychosis Risk Calculator (Cannon et al., 2016) combines SIPS re-
sults with those of several additional assessments to improve the pre-
dictive model, but the combined assessments take several hours to
administer. The Prodromal Questionnaire instruments including the
Brief Version (PQ-B) were developed as screening instruments to iden-
tify CHR individuals (Loewy et al., 2005, 2011a). Although other instru-
ments have been developed for screening purposes, the PQ-B is the
most well established self-report screener for CHR status (Jarrett et al.,
2012; Kline et al., 2012a, 2012b; Loewy et al., 2011b; Okewole et al.,
2015). The measure yields a high false-positive rate for CHR status,
however, which may render it unsuitable for widespread use as a
screener in general populations (Kline et al., 2012b; Xu et al., 2016).
Fusar-Poli et al. (2017) have also developed a model that uses
demographic variables and current diagnosis to predict progression to
psychosis, but themodel is not speciﬁc to early psychosis or schizophre-
nia. Kobayashi et al. (2008) validated the PRIME Screen-Revised (PS-R)
against 6-month conversion in a Japanese population, but only four peo-
ple in their study actually converted. Given the low prevalence of early
psychosis and the resources required for a clinician-administered as-
sessment, it is desirable to have a highly speciﬁc self-report screener
for early psychosis to promote appropriate early intervention (Cohen
and Marino, 2013; Comparelli et al., 2014).
In an earlier project (Brodey et al., 2018a), we developed a self-
report item bank to serve as the foundation for developing an early psy-
chosis screener. We assembled a panel of experts and implemented a
rigorous survey item development, modiﬁcation, and selection process.
This process included 40 participants and up to ﬁve iterative rounds of
cognitive interviewing per item (Willis, 2005). We identiﬁed a subset
of 148 items that were well understood by CHR individuals and public
sector mental health care recipients, and that our expert panel believed
would cover the breadth of concepts associated with the prodromal pe-
riod and early psychosis. In further analysis of this sample, we used
Spectral Clustering and Minimum Redundancy Maximum Relevance
procedures to select a subset of self-report items, the Early Psychosis
Screener (EPS)-26, that could differentiate Clinically Low Risk (CLR)
and CHR individuals with excellent accuracy (ROC AUC = 0.899), al-
though accuracy for discriminating CHR from ﬁrst episode psychosis
(FEP) was lower (AUC = 0.614) (Brodey et al., 2018b). A printable
copy of the complete EPS-26 assessment can be found at www.eps.
telesage.org.
In initiating the present study, wewanted to validate a screening in-
strument against true psychotic conversion using a patient sample gath-
ered from established CHR clinics afﬁliated with the North American
Prodrome Longitudinal Study (NAPLS) and Center of Prevention and
Evaluation (COPE, New York State Psychiatric Institute). We chose our
analytic methods a priori, before any exploration of possible predictive
models for actual psychotic conversion. In developing this plan, our ini-
tial goalwas to develop an assessment thatwould identify individuals in
need of in-person evaluation and possible treatment. Our plan included
a Spectral Clustering Analysis followed by Support Vector Machine
(SVM) development and testing.
Our hypothesis was that Spectral Clustering Analysis followed by a
nonlinear SVM analysis could be used to put together a subset of the
148 self-report items that would accurately identify people who were
at high risk of experiencing a psychotic disorder within 12 months
and/or who had already experienced a ﬁrst episode psychosis (FEP).
Whereas the norm has been to validate against a proxy outcome such
as CHR status, we hoped that validating against conversion or FEP status
would result in a more useful assessment.
2. Methods
2.1. Participants
Recruitmentwas conducted at eight clinical sites: Calgary, NewYork
State Psychiatric Institute, Emory, UCLA, UCSD, UNC-CH, Yale, and
Zucker Hillside Hospital. TeleSage served as the only non-clinical re-
cruitment site. All participants provided IRB-approved informed con-
sent. Exclusionary criteria included: presence of a medical condition
known to affect the central nervous system, estimated IQ b70, and age
b14 or N35. The recruitment procedures for the NAPLS sites and COPE
were based on the Criteria of Psychosis-risk Syndromes (COPS), which
are delineated in the SIPS, and have been comprehensively described
in the literature (Addington et al., 2012; Brucato et al., 2017).
Clinical participants in this study were recruited from a pool of pa-
tients referred to a NAPLS research site or the COPE research clinic for
evaluation of psychosis risk. All participants were already receiving a
SIPS as part of their evaluation for the primary study (see Miller et al.,
2003 for a description of the SIPS assessment procedures) and were
asked to participate in the Early Psychosis for Screener for Internet
(EPSI) study. For this study, the SIPS scores were used as described by
McGlashan et al. (2001) to divide help-seeking participants into three
eligible groups: CLR, CHR, and FEP. (Please note that attenuated positive
symptoms better accounted for by another psychiatric condition, as
assessed using the SCID, represented an exclusionary criterion.) CLR
participants were those who were referred to the specialty clinic, but
who were found to have a SIPS P score of 1 or 2. All participants com-
pleted paper assessments including demographic items, our 148 test
items, and the PQ-B.
We also recruited an independent sample of non-clinical control
participants in Chapel Hill, North Carolina. These individuals were
half-time or greater students, between the ages of 18 and 35, with no
history of mental health treatment during the previous 2 years. (We
did not conduct a structured interview to conﬁrm an absence of CHR
or FEP in the control population.) These individuals were not followed
longitudinally.
2.2. Items
Webegan the study by administering the 148 test items. Afterwards,
we removed items that might lead to spurious differentiations for rea-
sons unrelated to the true likelihood of 12-month conversion. For this
reason, we removed the demographics items. We also removed all
data on participants' alcohol and drug use from the algorithm develop-
ment process. Drug usage varied greatly and no particular drug other
than marijuana was regularly endorsed. We also considered the poten-
tial inaccuracy of self-report drug use data. Finally, we removed items
which were not applicable to all participants (i.e., speciﬁc work- and
study-related items). In all, we removed 24 items from the analysis a
priori, leaving 124 test items. Although it is certainly possible that
some of these 24 items would have yielded useful information, given
our limited sample size, we did not want to risk the need for post hoc
analysis.
2.3. Spectral clustering analysis
A detailed description of the spectral clustering techniques employed
in this study can be found in the online supplement (Shi andMalik, 2000;
Ng et al., 2001; von Luxburg, 2007).
2.4. Support vector machine classiﬁers
SVM classiﬁers were trained to predict, given an individual's re-
sponses to the EPSI items, whether this individual would meet diagnos-
tic criteria for a psychotic disorder within 12 months or was already
experiencing an FEP. SVMs are a versatile class of supervised machine-
learning methods that can be trained to learn linear or nonlinear
input-output relations (Schölkopf and Smola, 2002; Vapnik, 1998).
SVMs do not suffer much from the local minima problem of getting
stuck in a suboptimal solution of the task. They have excellent general-
ization abilities and thus a reduced likelihood of overﬁtting. Here we
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used the SVMlight software package (available for download at http://
svmlight.joachims.org/) (Joachims, 1999).
Our a priori chosen approach was to use the bootstrap aggregating
method (Breiman, 1996) to develop 50 radial basis function (RBF)-ker-
nel SVM classiﬁers, each trained on 80% of all the subjects, selected ran-
domlywith replacement from the entire pool. Once developed, these 50
classiﬁers were used together as a battery to classify any given partici-
pant by averaging their scores, assigning him or her to either of the
two discriminated groups based on whether the average battery score
was above or below the classiﬁcation threshold (default = 0). Only de-
fault SVM parameters were used, except for the gamma parameter,
which speciﬁes the RBF variance. Based on our earlier SVM studies of
early psychosis item pool responses, we set gamma = 0.01. Cross-
validation was done using the standard leave-one-out approach. A
more detailed description of the SVM training and testing techniques
employed in this study can be found in the online supplement.
The choices of (1) using 50 classiﬁers, (2) training each of them on
80% of subjects, and (3) using nonlinear SVMs with RBF kernel whose
parameter gammawas set to 0.01, weremade a priori, based on general
considerations, in order to avoid inﬂating the classiﬁer performance and
to allow cross-validation using the leave-one-out approach. Several
post-hoc models were also explored.
3. Results
3.1. Participants
We recruited a total of 353 participants from the eight early psycho-
sis sites where SIPS screening is part of the standard protocol. Six of the
clinical participants had missing intake data. (In most cases they had
missed one or more pages of the test items.) The response sets from
these participants were excluded from further analysis, leaving 347
clinical response sets. These can be further divided into: 71 CLR, 234
CHR, and 42 FEP. We also recruited 107 students from Chapel Hill,
North Carolina to serve as non-clinical control (NCC) participants. Over-
all, participants were 20.5 ± 4.4 years old and 41% males.
We attempted to follow all 234 CHR participants longitudinally for a
minimum of 12 months and for up to 24 months. Eighty-ﬁve of these
participants were lost to follow-up at the various sites either prior to
converting or prior to the end of the initial 12-month period. The re-
maining 149 participantswere followed either to the time of conversion
or for aminimum of 12months. Thirty-four of the 149 CHR participants
converted during the ﬁrst 12 months, and 5 participants converted be-
tween 12 and 24 months. Seventy-ﬁve did not convert during the ﬁrst
12 months, but were lost to follow-up prior to 24 months. Thirty-ﬁve
participants had not converted after 24months. In summary, 34 partic-
ipants converted to psychosis within one year and 115 participants are
known not to have converted during the ﬁrst 12 months.
For the purpose of training SVMs, participants were combined into
two groups. The non-converter group, Group NC, included CLR partici-
pants (n = 71), as well as CHR participants who did not convert even
after 2 years (n = 35), for a total of 106 participants. We selected this
population for SVM training to ensure that we would train SVMs with
a broad group of participants whowere referred for evaluation at a spe-
cialty clinic, but whowere found to be in a low risk group or not to have
converted during the longest possible follow-up period. The converter
group, Group C, included FEP participants (n = 42) as well as those
CHR participants who converted within the ﬁrst 12 months after their
initial SIPS screening (n = 34), for a total of 76 participants. Training
SVMs with these groups would minimize the likelihood that we
would misclassify participants who might beneﬁt from an in-person
evaluation and served tomaximize the public health relevance of the ul-
timate EPSI.
The CHR participants who converted between 12 and 24 months
after initial screening (n = 5) were not used in training SVMs as there
were too few for us to be able to use them to develop algorithms to
predict 24-month conversion. CHR participants who did not convert
during the ﬁrst 12 months and who dropped out of the study between
12 and 24 months after intake (n = 75) were also excluded from the
SVM classiﬁer training as a small number of these participants might
have converted between 12 and 24 months after intake. Data from
these individualswere subsequently used as part of an independent val-
idation of the algorithms.
3.2. Item reduction using spectral clustering analysis (SCA)
When SCA was performed, the 124 items formed two distinct clus-
ters. An overwhelming majority of the 64 positive items target either
psychosis or mania. In contrast, the 60 negative items predominantly
target depression, anxiety, and social and generalwork/school function-
ing.We therefore conﬁned our SVM study exclusively to the 64 positive
items. It should be pointed out that our spectral clustering procedure
did not rely on the membership of the individuals in the C and NC
groups to partition the 124 items. In the current study, we did not
have sufﬁcient power to reduce the 64 items relating to positive symp-
toms or to integrate the 60 negative symptom items into our algorithm
development process. Please see the online supplement for a more de-
tailed description of the SCA results.
3.3. EPSI discriminative performance
The 64 items of the positive spectral cluster were used as inputs to a
bootstrap aggregating battery of 50 SVMs, trained to classify any given
individual as belonging to either Group C or Group NC. Each SVM was
trained on 80% of all the subjects in Groups C andNC, selected randomly
with replacement from the entire pool after one subject was removed
and saved for leave-one-out cross-validation testing.
The cross-validated Group C vs. Group NC performance of the 50-
SVM battery is listed in Table 1. For a comparison, Table 1 also lists the
same classiﬁcation performance of other screening instruments;
i.e., SIPS, PQ-B at the published sum score cut-offs of 3 and 6, and EPS-
26 at the published sum score cut-off of 33.5. Although CLR subjects in
this project were not followed to determine whether they converted
after the initial screening, in Table 1 we used an existing estimate that
1.8% of those individuals would have converted (Webb et al., 2015).
Table 1 shows that the EPSI is superior to the SIPS, PQ-B, and EPS-26
in its avoidance of false positives. Access to a full list of the EPSI items
and to the self-scoring online EPSI can be found at www.eps.telesage.
org.
In addition to its cross-validation testing on Group C and Group NC
individuals, EPSI was also applied to the independent sample of 107
NCC individuals, as well as 5 CHR individuals who did not convert dur-
ing the ﬁrst 12 months but did convert during the subsequent
12 months, and 75 CHR individuals who did not convert during the
ﬁrst 12 months, but were lost to follow up prior to 24 months (the
last 2 categories are CHR deﬁnite 1-year non-converters). Table 2 lists
the numbers of individuals in each category (non-clinical control, CLR,
Table 1
Classiﬁcation performance of SIPS, PQ-B, EPS-26 and EPSI screeners in correctly
distinguishing between FEP/converter subjects (Group C) and non-converter subjects
(Group NC). The PQ-B was scored with published sum score cutoffs of 3 and 6 (Loewy
et al., 2011a). The EPS-26 was also scored at its published sum score cutoff of 33.5. True
Positive Fraction – probability that a Group C subject will be correctly classiﬁed as such.
False Positive Fraction – probability that a Group NC subject will be misclassiﬁed as Group
C. Positive Predictive Value – probability that a subject classiﬁed as Group C does indeed be-
long to Group C.
Method SIPS PQ-B
≥3
PQ-B
≥6
EPS-26
≥33.5
EPSI EPSI+
SIPS
True Positive Fraction (%) 98.2 84.2 71.1 81.6 51.3 76.3
False Positive Fraction (%) 33.0 51.9 37.7 45.3 11.3 8.5
Positive Predictive Value (%) 68.5 53.8 57.5 56.4 76.5 86.6
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CHR deﬁnite 2-year non-converters, CHR deﬁnite 1-year non-
converters, CHR 1-year converters, and FEP) who were classiﬁed as be-
longing to Group C by each of the studied screening instruments. It
shows that EPSI had a lower probability of mistakenly classifying non-
clinical, CLR, or CHR non-converter individuals as converters than
othermethods. Also note that EPSI classiﬁcation performance on the in-
dividuals in the non-clinical and CHR 1-year non-converter categories,
which were not used in SVM training, agrees closely with its cross-
validation performance on the individuals in the CLR and CHR 2-year
non-converter categories, respectively. However, the false negative
rate of classiﬁcation was also lower than with the other screeners in
the FEP subjects and in the SIPS CHR converters.
Focusing speciﬁcally on the ability of the studied screeners to predict
who, among CHR individuals in the present dataset, will convert within
one year, we list their positive predictive values (PPV), sensitivity, and
speciﬁcity in Table 3. (For Table 3we did not include any CLR or FEP par-
ticipants.) Since Table 3 relies exclusively on participants who were
found to be CHR on the SIPS, the results reﬂect the performance statistics
of the SIPS alone or in combination with each of the instruments noted.
Again, we ﬁnd that the PPV and speciﬁcity of the EPSI + SIPS was superior
to the SIPS alone, or PQ-B + SIPS, or EPS-26 + SIPS. The PQ-B did not ap-
pear to add information when administered in conjunction with the SIPS.
Our battery of 50 SVMs classiﬁes any given individual based on his or
her average battery score. This battery score can be viewed as an SVM-
learned estimation of a person's position on a “psychotic thinking” spec-
trum. This spectrum is shown in Fig. 1, which plots the battery-averaged
EPSI scores of all studied groups. In the ﬁgure, information on 30-day
drug and alcohol use was re-introduced, and the 107 non-clinical con-
trols were divided into two groups. The ﬁrst group comprised the 60
participants who denied using any drugs other than alcohol to get
high during the previous 30 days. The second group of 47 participants
reported that they had used drugs at least once in the previous
30 days to get high.
After performing the analyses selected a priori, we explored several
post-hoc analyses. These included, for example, using all 124 items, but
condensing the items into 30 variables using PCA. We also explored
varying model parameters and using a linear SVM model. We explored
training the algorithmwith different sub-populations, e.g. only CHR in-
dividuals using a simple outcome variable of conversion vs. non-
conversion. These models tended to converge on similar results. Indi-
vidual models were somewhat superior with regard to speciﬁc pur-
poses, but none of the additional models tested were clearly superior
overall.
4. Discussion
Wewish to emphasize that the analytic techniques employed in this
study were selected a priori. SCA enabled us to identify a useful and co-
hesive subset of items in order to improve the item-to-participant ratio.
Since the SCA technique employed did not take group assignment into
consideration, the item reduction process did enhance thepredictive ca-
pacity of the items relative to the item group as a whole. Although it is
possible that other machine learning strategies might have yielded su-
perior prediction, we considered nonlinear SVM to be among the best
a priori strategies for developing a predictive algorithm. We did not
test any other algorithms.
Overall, the PPV for the EPSI at the default threshold was superior to
that of the SIPS, the EPS-26, and the PQ-B. Furthermore,while the SIPS is
a loosely structured interview that requires substantial training and
about 90 min to administer, the EPSI is a 64-item self-report assessment
that is intended to have a 5th-grade reading level and take b12 min to ad-
minister. The PQ-B is the primary alternative self-report early psychosis
screener; it waswell ahead of its timewhen it was ﬁrst releasedwith 96
items (Loewy et al., 2005). It is now comparatively short at 21 items, yet
even at the more speciﬁc upper published cut-off of 6 it is probably too
sensitive and not speciﬁc enough to be used for screening either a gen-
eral population or individuals seeking an evaluation for early psychosis.
The EPS-26, developed as an earlier part of this project, was validated
against SIPS status andmay provide a simple strategy for identifying in-
dividuals who would score in the CHR range on the SIPS, but it was not
validated against true conversion and is considerably less accurate than
the EPSI at predicting true conversion. Just as the length of the PQ-96
was reduced when additional data became available, we expect that
Table 2
Percent (number) of participants in each category who were classiﬁed as belonging to Group C (i.e., FEP/converter subjects). * marks categories that were not used in SVM training.
Method PQ-B
≥3
PQ-B
≥6
EPS-26
≥33.5
EPSI
Non-Clinical* (n = 107) 27.1 (29) 12.2 (13) 29.0 (19) 0.9 (1)
CLR (n = 71) 29.6 (21) 16.9 (12) 19.7 (14) 4.2 (3)
CHR-NC (n = 35) 2-year non-converters 97.1 (34) 80.0 (28) 97.1 (34) 25.7 (9)
CHR-NC* (n = 80) 1-year non-converters 92.5 (74) 72.5 (58) 83.8 (67) 21.3 (17)
CHR-C (n = 34) 1-year converters 85.3 (29) 70.6 (24) 79.4 (27) 47.1 (16)
FEP (n = 42) 83.3 (35) 71.4 (30) 83.3 (35) 54.8 (23)
Table 3
Statistical performance of the SIPS alone or a combination of the SIPS with (a) the PQ-B
with the published cutoffs of 3 and 6, or (b) the ESP-26 with a published cutoff of 33,5,
or (c) the EPSI in predicting actual conversion of CHR participants within 12 months.
Method SIPS PQ-B
≥3
PQ-B
≥6
EPS-26
≥33.5
EPSI
Positive Predictive Value (%) 22.8 21.2 21.8 21.1 38.1
Sensitivity (%) 100 85.3 70.6 79.4 47.1
Speciﬁcity (%) 0 6.1 25.2 12.2 77.4
Fig. 1. Average EPSI scores for six studied groups: (1) NCCs who denied any 30-day drug
use, (2) NCCs reporting some 30-day drug use, (3) CLR, (4) 12-month non-converters,
(5) psychotic converters, and (6) FEP participants. The error bars are standard error of
the mean. (SVM scores express relative proximity of tested data points to the
classiﬁcation boundary.)
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the length of the 64-item EPSI will also decrease over time. Since items
with low predictive value generate noise in SVM algorithms, a shorter
version of the EPSI is likely to be more accurate than the longer version.
The EPSI is the ﬁrst self-report assessment that can be used effectively to
screen and refer large numbers of people, who are thought by friends, rela-
tives, or primary care clinicians to be at increased risk of psychosis, for in-
person evaluation by a licensed professional. Due to its high positive predic-
tive value, the EPSI can serve as the wide end of a funnel that brings high-
risk people in for evaluation as part of routine clinical care or a speciﬁc re-
search protocol. Because of it uses machine leaning scoring algorithms,
administration over the internet via a smartphone or laptop is ideal.
The EPSI may also have an important role at the narrower end of the
funnel. In our study, only 23% of all CHR individuals actually converted.
In a clinical trial this means that if all CHR individuals are randomized,
77% of the participants in both the active and control arms have only a
minimal potential to improve, even with a highly efﬁcacious interven-
tion, since they donot have the condition. In this situation, the beneﬁcial
effects of the intervention are unlikely to be recognized; however, if the
SIPS and EPSI have a combined ability to identify a population of CHR in-
dividuals, 38% ofwhomwill convert, as they did in our study, then itwill
be easier to identify an effective intervention.
There is an added beneﬁt to using the EPSI. Because it characterizes
the severity of granular symptoms on a Likert scale, it is possible to iden-
tify the speciﬁc symptoms that improve as a result of an intervention.
This is especially important because we recognize that schizophrenia
is a heterogeneous set of disorders. By identifying speciﬁc symptom
clusters that are responsive to an intervention, the EPSI should in the fu-
ture further improve the signal-to-noise ratio in clinical trials. This will
further increase the likelihood that an efﬁcacious intervention will be
identiﬁed. Just as SVM classiﬁers can be used to assess the combined
risk of speciﬁc patterns of alleles in an individual, it should also be pos-
sible to use the SVM classiﬁers to dissect associated patterns of
symptoms.
This study used the leave-one-out cross-validation model, but it is
noteworthy that the non-clinical sample was entirely independent. Of
these 107 participants, who were recruited at a separate site and
whose data were NOT used in algorithm development, b1% of partici-
pants were identiﬁed as possible converters. Similarly, data from the
80 CHR individuals in the 12-month non-converter sample were NOT
used in algorithm development. But, among these 80 individuals, only
21% screened positive on the EPSI. This ﬁnding is fully consistent with
and tends to conﬁrm our results.
5. Limitations
A marked limitation of the EPSI is its low sensitivity at recognizing
FEP or future converters in the CLR + CHR population: at its default
SVM classiﬁcation threshold of ‘0’, it has a low sensitivity of 0.5 although
a high speciﬁcity of 0.89. At this threshold, for every person identiﬁed
with an FEP or as being a future CHR converter, one person will be
missed. Sensitivity can be improved by reducing the SVM classiﬁcation
threshold to, for example, −0.7 (Fig. 2). This yields a sensitivity of
0.78 and a speciﬁcity of 0.58. Still, these sensitivities and speciﬁcities,
while within the range of many established medical screeners, e.g. the
Fasting Plasma Glucose Test for gestational diabetes (Maxim et al.,
2014), are not high enough to consider the EPSI a diagnostic tool. Any
use of the EPSI must take into consideration this high false negative
rate. Our hope is that the EPSI will be used as a screener to identify indi-
viduals who should be referred to specialty providers for further in-
person evaluation for prodromal status. Using the EPSI sub-population
curves presented in Fig. 2 and by estimating the true proportion of
‘non-clinical control’, ‘CLR’, ‘CHR non-converter’, ‘CHR converter’, and
‘FEP’ individuals in any population to be evaluated, the reader can gen-
erate the anticipated EPSI screening results, PPV and NPV. An ROC curve
for the EPSI is provided in the online supplement, Fig. S2. In determining
the EPSI's clinical utility for any given population, one must consider
these metrics as well as the purpose of the investigation. In the hypo-
thetical scenarios described below, we have set the EPSI cut-off either
at its default SVM classiﬁcation threshold of 0, at a somewhatmore sen-
sitive threshold of−0.7, or at a fairly speciﬁc threshold of +0.4. One so-
lution to the low sensitivity of the EPSI would be to have all participants
who screen between ‘-0.7’ and ‘0’ on the EPSI rescreened after 8 weeks.
While this option is still under study, rescreening ormeasuring progres-
sion may ultimately improve the sensitivity of the screening system.
Scenario 1: A clinic selectively screens new clients between the ages
of 14 and 35who seem to have unusual thoughts or perceptions, orwho
exhibit social withdrawal. We assume that 5% are experiencing an FEP,
5% will be ‘CHR converters’, and 15% will be ‘CHR non-converters’. The
remaining 75% of the sample are CLR. For this enriched sample, we
want high sensitivity. At a cut off of “-0.7”, for every 100 people
screenedwewill identify 8 true positives, 29 false positives, 2 false neg-
atives, and 61 true negatives. For every CHR Converter that we identify,
we will identify 2.75 false positives from among the CHR non-
converters, a ratio that is close to that of the SIPS. The screening ratio
for true positives and false positives is 28%.
Scenario 2: The same clinic decides to screen all new clients using
the EPSI. About 1% of the total sample has FEP, 1.25% of the individuals
screened will be CHR-converters, and 3.75% will be CHR non-
converters. The remaining 94% are somewhere between CLR and
NCCs. For this scenario we will assume that they are CLRs, as this is
the more challenging screening scenario. Based on this scenario and
the curves shown in Fig. 2 for the EPSI, and using a cut off of “0” to pro-
mote speciﬁcity, if we screen 100 individualswewill identify 1 true pos-
itive, 1 false negative, 5 false positives, and 93 true negatives. Thus, for
every 6 people sent for in-person screeningwith the SIPS, we will iden-
tify 1 true positive and 5 true negatives. For every CHR converter we
identify we will identify 1 false positive from among the CHR non-
converters, a ratio that is much better than that of the SIPS.
Scenario 3: An investigator who wishes to screen a very large num-
ber of potential participants quickly for an early psychosis or FEP study
might want to use the online assessment to screen help-seeking indi-
viduals between the ages of 18 to 25. Let's assume that among each
1000 people assessed, 5 have FEP, 5 are CHR-converters, 15 are CHR
non-converters, 200 are CLRs, and 775 are non-clinical controls. In
order to avoid a high false positive rate, he or shemightwant to increase
the threshold to +0.4. This would still enable the EPSI to identify about
36% of FEP and CHR converters. It would also identify about 10% of CHR
non-converters, amajority of whomwould go on to develop other diag-
nosable disorders. The screening would miss approximately 64% of the
FEP and CHR converter populations. However, at this high stringency,
Fig. 2. Probability that an individual taken from either of the studied groups will be
classiﬁed by the EPSI as belonging to Group C (FEP/converter) plotted as a function of
the SVM classiﬁcation threshold. By plotting a vertical line anywhere along the x axis, it
is possible to assess the impact of changing the threshold on classiﬁcations within each
sub-group and to model how the EPSI will do in diverse screening situations.
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none of the non-CHR individuals would be identiﬁed as false positives.
In certain situations, high-volume, low-cost screening in somewhat
enriched populations could prove to be a cost-effective screening strat-
egy to promote early identiﬁcation or recruitment.
The second potential limitation of this study would be overestima-
tion of the accuracy of the assessment. As described above, we took
many precautions to prevent inﬂation of the accuracy of the EPSI; how-
ever, repeating the evaluation with a complete fully independent sam-
ple is the only sure way to demonstrate the accuracy of the assessment.
While the high speciﬁcity of the EPSI may make it an excellent
screener for use in making specialty referrals, it is not a diagnostic
tool. People can respond to self-report assessments in a variety of
ways for many complex reasons. For example, among the FEPs there
were several participants who endorsed very few symptoms, despite
being rated SIPS six by the interviewer. Our hypothesis is that these par-
ticipants minimized their symptoms on the self-report assessment, but
that the interviewer was able to elicit the underlying symptoms. To im-
prove the accuracy of the EPSI, andwith the help of NAPLS and COPE in-
vestigators, we developed a few items to identify people who tend to
‘minimize’ or ‘emphasize’ the severity of their symptoms. In the future,
this short scale should provide independent information that may in-
crease the accuracy of the EPSI. At presentwe believe that only a special-
ist should make a diagnosis of APS or FEP.
An additional limitation of the EPSI is that it was not able to distin-
guish effectively between prodromal and FEP states. This suggests that
it is difﬁcult to demarcate an exact line separating the later prodromal
and early FEP periods, most likely because the distinction rests on the
client's ‘conviction’ regarding the reality of his or her delusions or hallu-
cinations. “Conviction” itself is probably best viewed as an episodic trait
rather than a single binary variable.
In the future, since attenuated psychotic syndrome (APS) and per-
haps even FEP represent a progressive continuum of symptoms, we ex-
pect that a longitudinal use of the EPSImay bemost clinically useful: it is
likely that the progression of EPSI scores over several administrations
might prove more predictive of conversion than individual EPSI scores
at any single point in time. Multi-step screening, using items relating
to negative symptoms, might also increase overall prediction accuracy.
The EPSI may also prove useful for tracking the progression of APS in
clinical trials.
6. Conclusions
The EPSI is the ﬁrst self-report assessment validated against 12-
month conversion that can be used effectively to screen and refer
large numbers of people who are thought by friends, relatives, or pri-
mary care clinicians to be at increased risk of psychosis. The EPSI is
not a diagnostic tool, but it currently has the potential to be used for
public health screening, both to decrease the duration of untreated psy-
chosis and to bring eligible individuals into specialty clinical care set-
tings and clinical trials aimed at identifying more effective treatments
for early psychosis. By combining the EPSI with the SIPS, we can further
increase the PPV of each individual assessment. Despite its strengths,
the implications of the false negative rate must be taken into consider-
ation in any speciﬁc screening scenario. The cut-off for the EPSI can eas-
ily be modiﬁed to increase or decrease sensitivity of the assessment
based on purpose.
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